OPKO and Pfizer Receive Regulatory Clearance for Global Agreement
OPKO Health, Inc. and Pfizer Inc. announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone. The closing follows...
View ArticleOPKO Submits Investigational New Drug Application to Initiate a Phase 2a...
OPKO Health, Inc. announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO’s long-acting version of...
View ArticleTwelve Months Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone...
OPKO Health, Inc. announced the presentation of two posters at the 97th Annual Meeting of the Endocrine Society (ENDO 2015) on March 5th, 2015 in San Diego, California, that included twelve months data...
View ArticleOPKO Presented New Data at International Society on Thrombosis and...
New Preclinical Data further demonstrate the safety and efficacy of MOD-5014 (FVIIa -CTP) for both Intravenous and Subcutaneous Administration OPKO Health, Inc. presented new data on its long-acting...
View ArticleOPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth...
OPKO Health, Inc. has completed enrollment in the single pivotal Phase 3 trial of its long acting human growth hormone (hGH-CTP) in growth hormone deficient (GHD) adults. The trial is designed to...
View ArticleOPKO Biologics Presents Clinical Data on its Long-acting Human Growth Hormone...
OPKO Biologics presented clinical data from its completed 12-month hGH-CTP Phase 2 pediatric growth hormone deficiency clinical study in two oral presentations at the 54th Annual Meeting of the...
View ArticleOPKO Biologics to Host Symposium to Present Clinical Data on its Long-acting...
OPKO Biologics will host a symposium at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology and will present the complete 12-month pharmacokinetic, pharmacodynamic, safety and...
View Article